Plain-English translation of NCT06683950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a newer eye injection for people with wet age-related macular degeneration (a condition that damages the center of your vision). You would be eligible if your current treatment hasn't worked well enough—meaning fluid is still building up in your eye despite regular injections. The study will see whether switching to this higher dose helps clear that fluid and improve your vision.
Many people with wet macular degeneration don't respond well enough to current treatments, and their eyes continue to fill with fluid even after regular injections. This medication was recently approved by the FDA and showed promise in earlier studies, so researchers want to test whether it works better for people like you who haven't had success with other options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive injections of the new medication directly into your eye at regular intervals over 76 weeks (about 18 months). You'll have frequent clinic visits to monitor how well the treatment is working—doctors will use imaging to look for fluid in your eye and check your vision. Throughout the study, you'll be watched carefully for any side effects, though this medication has shown a good safety profile so far.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
South Korea